-

AHF: Biden Chides Drug Industry, Urges Enforcement of 340B Statute

WASHINGTON--(BUSINESS WIRE)--AIDS Healthcare Foundation (AHF) welcomed U.S. President Joe Biden’s remarks chiding the drug industry and defending the 340B drug pricing program. During an appearance in Culpeper, VA, with U.S. Health and Human Services Secretary Xavier Becerra in U.S. Rep. Abigail Spanberger’s (D-VA) congressional district, Biden spoke about his administration’s work to lower prescription drug costs and thanked Rep. Spanberger in particular for her “relentless” work ensuring that the 340B statute “is actually enforced.”

The 340B Drug Pricing Program is a U.S. government program that requires drug companies to provide drugs to eligible nonprofit, safety net organizations at a discount. The intent of the program is to allow these nonprofits to “stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services.” This program, which reaps enormous benefits, costs taxpayers nothing.

Because they have violated the law, the U.S. Health Resources Services Administration (HRSA) has taken action against drug companies for their illegal refusal to offer 340B discounts to 340B covered entities. As many as 13 drug companies have refused to comply with HRSA’s demands to obey the law and resume offering 340B pricing to contract pharmacies. Their unlawful refusal to offer discounts through contract pharmacies has resulted in overcharges and put the lives of millions of Americans at risk.

AIDS Healthcare Foundation (AHF), the largest global AIDS organization, currently provides medical care and/or services to over 1.7 million clients in 45 countries worldwide in the US, Africa, Latin America/Caribbean, the Asia/Pacific Region and Europe. To learn more about AHF, please visit our website: www.aidshealth.org, find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare

Contacts

Ged Kenslea
Senior Director, Communications, AHF

+1.323.791.5526 [cell]
+1.323.308.1833 [work]
gedk@aidshealth.org

John Hassell
National Director of Advocacy, AHF
+1.202.774.4854 [cell]
John.hassell@aidshealth.org

AIDS Healthcare Foundation


Release Summary
AHF: Biden Chides Drug Industry, Urges Enforcement of 340B Statute
Release Versions

Contacts

Ged Kenslea
Senior Director, Communications, AHF

+1.323.791.5526 [cell]
+1.323.308.1833 [work]
gedk@aidshealth.org

John Hassell
National Director of Advocacy, AHF
+1.202.774.4854 [cell]
John.hassell@aidshealth.org

More News From AIDS Healthcare Foundation

AHF: Florida Lawmakers Reverse HIV Drug Cuts, Restoring Coverage for Thousands

TALLAHASSEE, Fla.--(BUSINESS WIRE)--Thousands of Floridians living with HIV will keep the medication that keeps them alive, after the Florida Legislature today passed a state budget that reverses this year's cuts to the AIDS Drug Assistance Program (ADAP). The budget returns eligibility to 400 percent of the federal poverty level, brings back the medications the Department of Health had dropped, including Biktarvy, funds the program with $75 million, and adds independent oversight. "This is wha...

AHF Calls for Access and Dignity on Menstrual Health Day

LOS ANGELES--(BUSINESS WIRE)--AIDS Healthcare Foundation (AHF) joins the global commemoration of Menstrual Health Day with events across nearly 50 countries, highlighting the importance of reducing period stigma and expanding access to affordable menstrual products—critical steps in protecting overall health and reducing vulnerability to HIV and other sexually transmitted infections. Menstrual Health Day is observed annually on May 28. Around the world, barriers to menstrual health continue to...

Ebola Crisis Exposes Failure of Current Global Health Architecture, says AHF

LOS ANGELES--(BUSINESS WIRE)--As Uganda and the Democratic Republic of the Congo (DRC) confront a rapidly evolving Ebola outbreak, AIDS Healthcare Foundation (AHF) warns that the crisis highlights persistent weaknesses in the world’s ability to respond quickly and equitably to emerging infectious disease threats. The current outbreak involves the Bundibugyo strain of Ebola virus, for which no approved vaccines or therapeutics currently exist, heightening concerns among global health officials a...
Back to Newsroom